These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22293302)

  • 1. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
    Gersch ED; Gissmann L; Garcea RL
    Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
    Karanam B; Jagu S; Huh WK; Roden RB
    Immunol Cell Biol; 2009; 87(4):287-99. PubMed ID: 19421199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic papillomavirus vaccines.
    Ribeiro-Müller L; Müller M
    Clin Dermatol; 2014; 32(2):235-47. PubMed ID: 24559559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
    Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
    Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
    Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
    Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
    Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
    Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
    Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.
    Cho H; Lee HJ; Heo YK; Cho Y; Gwon YD; Kim MG; Park KH; Oh YK; Kim YB
    PLoS One; 2014; 9(4):e95961. PubMed ID: 24759938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic HPV DNA vaccines.
    Lin K; Roosinovich E; Ma B; Hung CF; Wu TC
    Immunol Res; 2010 Jul; 47(1-3):86-112. PubMed ID: 20066511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in Understanding Carcinogenetic Mechanisms of the Human Papillomavirus and Vaccines Based on Virus-like Particles].
    Zhao Z; Wang L; Ma B
    Bing Du Xue Bao; 2015 Mar; 31(2):180-6. PubMed ID: 26164945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
    Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
    Front Immunol; 2020; 11():606569. PubMed ID: 33343580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.